The global cardiovascular drug market

Quirk, Jeremy; Maidwell, Nicola
April 2004
International Journal of Medical Marketing;Apr2004, Vol. 4 Issue 2, p96
Academic Journal
Presents an overview of the global cardiovascular drug market. Expectation of the growth of the value of the cardiovascular market in future; Dependence of the size and shape of the cardiovascular market on strong and often opposing forces; Definition and treatment of the cardiovascular disease in terms of individual risk factors; Dependency of a drug's success in the cardiovascular market on the ability to improve patient health.


Related Articles

  • AJPCPD.  // Australian Journal of Pharmacy;Jul2012, Vol. 93 Issue 1106, p91 

    A quiz related to cardiovascular disease and role of statins and diet in its treatment is presented.

  • CHD patients should take statins at night.  // Pulse;11/18/2002, Vol. 62 Issue 44, p4 

    Focuses on the impact of taking statin at night on the cholesterol-lowering effect of coronary heart disease patients.

  • Starting statins for primary prevention of cardiovascular disease. Tunstall-Pedoe, Hugh // Heart;Nov2013, Vol. 99 Issue 21, p1547 

    An introduction to the journal is presented in which the editor discuss the prevention of cardiovascular diseases by prescription of statins, drugs that lower cholesterol levels, in general population.

  • Primary Prevention and Statins: Is It Just About Going to Class? Krasuski, Richard A. // Mayo Clinic Proceedings;Dec2008, Vol. 83 Issue 12, p1313 

    The article discusses various reports published within the issue including one on the study that examines the clinical outcomes of over 200,000 patients wherein statin therapy was initiated and another on the significance of statin therapy in the prevention of cardiovascular disease.

  • CARDIOVASCULAR DISEASE.  // MPR - Nurse Practitioners' Edition;Fall2013, Vol. 20 Issue 3, p3 

    The article lists several drugs for cardiovascular disease which include aranesp from Amgen, omontys from Affymax and Takeda and caduet from Pfizer Inc.

  • Statins and micronutrients: unanswered questions. McKee, Martin; Moat, Stuart J.; McDowell, Ian // Journal of the Royal Society of Medicine;Oct2004, Vol. 97 Issue 10, p459 

    The author reflects on issues underlying the widespread use of statins. He examines the objections to the evidence influencing the popularity of the drug. Statins, in several studies, are identified as putative agents that prevent cardiovascular diseases due to its direct effect on the enzyme...

  • STATINS. Reckless, John // Pulse;12/14/2006, Vol. 66 Issue 47, p26 

    The article presents questions and answers related to lipid lowering agents, statins. One of the questions presented inquires on the period by which lipid measurement be started after the statins therapy begins. Another asks on how could one ensure that target cholesterol levels are achieved in...

  • Effects of Statins on Nonlipid Serum Markers Associated with Cardiovascular Disease. Balk, Ethan M.; Lau, Joseph; Goudas, Leonidas C.; Jordan, Harmon S.; Kupelnick, Bruce; Kim, Linda U.; Karas, Richard H. // Annals of Internal Medicine;10/21/2003, Vol. 139 Issue 8, p670 

    Investigates the effects of statins on nonlipid serum markers associated with cardiovascular disease. Benefits of statin; Ability of statins to reduce risk for cardiovascular disease; Importance of nonlipid factors in the pathogenesis of atherosclerosis.

  • Cochrane review group responds to Abramson and colleagues' article on statins in low risk people. Huffman, Mark; Taylor, Fiona; Ebrahim, Shah; Abramson, John D.; Rosenberg, Harriet G.; Jewell, Nicholas; Wright, James M. // BMJ: British Medical Journal;3/8/2014, Vol. 348 Issue 7948, p26 

    The article presents the response of Mark Huffman and colleagues to the Cochrane Review on the use of statins as initial prevention for cardiovascular disease which was published in an article in the "British Medical Journal" and the corresponding response of the critics in defense of their...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics